Search results
Showing 136 to 150 of 1517 results for patients and public
a rapid assessment of flu product zanamivir. First public board meeting Register to attend a public board meeting . 2000...
People and communities - putting you at the heart of our work
NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.
People and communities - putting you at the heart of our work
NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.
In development Reference number: GID-TA11140 Expected publication date: TBC
In development Reference number: GID-TA11232 Expected publication date: 08 April 2026
Read the biographies of our medical technologies advisory committee members.
Find out more about NICE technology appraisals advisory committee D members
In development Reference number: GID-TA10979 Expected publication date: 11 March 2026
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development Reference number: GID-TA10994 Expected publication date: TBC
Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy
In development Reference number: GID-HTE10086 Expected publication date: 15 September 2026
Tell us what matters to you, your organisation or your community.
Tell us what matters to you, your organisation or your community.
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026
Find out more about NICE technology appraisals advisory committee D members
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .